Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2012 Oct 4;131(2):461–467.e5. doi: 10.1016/j.jaci.2012.07.055

Table 2.

Adverse event rates per 12 month period adjusted for exposure.

Period (months) Control* 0–12 12–24 24–36 36–48 >48

Subject-years exposure 15.0 69.0 61.1 59.2 57.8 39.9

Adverse Events
Number of events 319 643 374 300 349 184
Event rate** 2127 931.9 612.1 506.8 603.8 461.1

Serious AEs
Number of events 7 31 28 15 26 7
Event rate** 46.7 44.9 45.8 25.3 45.0 17.5
*

Subjects who received placebo in the placebo-controlled, double-blind mepolizumab trial (MHE100185)

**

Events per 100 subject-years exposure within period.

HHS Vulnerability Disclosure